The Department of Veterans Affairs is conducting a large clinical study to determine whether GLP-1 medications — the class that includes semaglutide — can help people with alcohol use disorder drink less. The Minneapolis VA Health Care System is leading the local arm of the trial alongside 18 other federal hospitals, and researchers plan to enroll more than 600 veterans.
Why the study matters
Researchers and clinicians say the trial could add another option to a treatment landscape that has seen little change in recent decades. Dr. Eric Dieperink, a Minneapolis VA staff psychiatrist heading the local effort, noted the scarcity of new medication therapies for alcohol use disorder.
“There hasn’t been a new medication treatment [for alcohol abuse] that’s been approved in over two decades,”
GLP-1 (glucagon-like peptide-1) drugs have produced dramatic headlines for weight loss in recent years, and some investigators are exploring whether the same biological effects that curb appetite might also reduce alcohol consumption. The medications work by mimicking a gut hormone that promotes a sense of fullness and slows digestion; they are available in both daily injectable and oral formulations.
How GLP-1s might influence drinking
Scientists are still sorting out the mechanism that could link GLP-1s to reduced alcohol use. Joseph Schacht, a researcher at the University of Colorado, said several possibilities exist: the drugs' appetite-suppressing effect, common side effects such as nausea, or changes in brain reward pathways.
“A more intriguing possibility is that semaglutide affects ... parts of the brain associated with reward, and that this effect makes people less likely to pursue rewarding substances like alcohol,”
Smaller trials have suggested heavy drinkers may cut back on alcohol while taking GLP-1 medications. The VA study aims to test that observation in a larger, multi-site veteran population to see whether the effect holds and whether the drugs could become a reliable treatment tool.
Context within existing treatments
Current medication options for alcohol use disorder include drugs such as naltrexone, which is also used for opioid-use disorder, but medication-assisted treatment remains uncommon. Federal surveys cited in the reporting indicate only about 3% of people with alcohol use disorder try medication-assisted treatment, reflecting longstanding treatment preferences and cultural attitudes favoring group-based abstinence programs like Alcoholics Anonymous.
- Scope: More than 600 veterans to be recruited across 19 VA sites.
- Drugs of interest: GLP-1 medications such as semaglutide; brand names widely recognized include Wegovy and Ozempic.
- Rationale: Possible effects include reduced appetite, nausea-related lowering of consumption, or changes to brain reward circuits.
Researchers say the prominence of GLP-1 drugs for weight management may also shape patient and clinician attitudes. Familiar brand names and visible results in obesity care could increase willingness to try the medications for alcohol-related problems, but experts caution that more evidence is needed before broader clinical adoption.
Trial details and next steps
The VA trial is intended to test efficacy and safety among veterans with alcohol use disorder. If the results show a meaningful reduction in drinking and acceptable side-effect profiles, GLP-1 medications could prompt renewed interest in pharmacological approaches to alcohol treatment — a shift from exclusively behavioral and group-based strategies that have dominated U.S. care.
| Item | Value |
|---|---|
| Number of VA sites | 19 (Minneapolis plus 18 others) |
| Target enrollment | More than 600 veterans |
| Existing medication uptake | About 3% of people with alcohol use disorder try medication-assisted treatment |
Investigators stressed that understanding how GLP-1s affect alcohol use will require careful analysis of trial outcomes, including whether observed reductions in drinking stem from appetite effects, adverse effects such as nausea, or direct modulation of reward pathways. The findings could influence clinical guidelines for treating alcohol use disorder and broaden treatment choices for veterans and the public.
As the trial proceeds, clinicians and people affected by alcohol use disorder will be watching for evidence that GLP-1s can safely and effectively reduce harmful drinking — and whether that evidence shifts longstanding perceptions about medication in recovery.
